Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Conditions: Corneal Edema; Corneal Defect; Anterior Chamber Inflammation; Ocular Pain; Corneal Staining; Visual Outcome; CME - Cystoid Macular Edema Interventions: Drug: Dextenza 0.4Mg Ophthalmic Insert; Drug: Prednisolone Phosphate 1%/Moxifloxacin 0.5%/Bromfenac 0.075% compound Sponsor: Nicole Fram M.D. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avelox | Cataract Removal | Cataracts | Moxifloxacin | Opthalmology | Pain | Prednisolone | Research